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Familial adenomatous polyposis (FAP) is caused by
germline mutations in the adenomatous polyposis coli
(APC) gene. Two promoters, 1A and 1B, have been
recognized in APC, and 1B is thought to have a minor role
in the regulation of the gene. We have identiﬁed a novel
deletion encompassing half of this promoter in the largest
family (Family 1) of the Swedish Polyposis Registry. The
mutation leads to an imbalance in allele-speciﬁc expression
of APC, and transcription from promoter 1B was highly
impaired in both normal colorectal mucosa and blood from
mutation carriers. To establish the signiﬁcance of promoter
1B in normal colorectal mucosa (from controls), expression
levels of speciﬁc transcripts from each of the promoters, 1A
and 1B, were examined, and the expression from 1B was
signiﬁcantly higher compared with 1A. Signiﬁcant amounts
of transcripts generated from promoter 1B were also
determined in a panel of 20 various normal tissues
examined. In FAP-related tumors, the APC germline
mutation is proposed to dictate the second hit. Mutations
leaving two or three out of seven 20-amino-acid repeats in
the central domain of APC intact seem to be required for
tumorigenesis. We examined adenomas from mutation
carriers in Family 1 for second hits in the entire gene
without any ﬁndings, however, loss of the residual
expression of the deleterious allele was observed. Three
major conclusions of signiﬁcant importance in relation to
the function of APC can be drawn from this study; (i)
germline inactivation of promoter 1B is disease causing in
FAP; (ii) expression of transcripts from promoter 1B is
generated at considerable higher levels compared with 1A,
demonstrating a hitherto unknown importance of 1B; (iii)
adenoma formation in FAP, caused by impaired function of
promoter 1B, does not require homozygous inactivation of
APC allowing for alternative genetic models as basis for
adenoma formation.
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Introduction
Familial adenomatous polyposis (FAP) is caused by
dominant inheritance of germline mutations in the
adenomatous polyposis coli (APC) tumor suppressor
gene. In classical FAP, mutation carriers develop
hundreds to thousands of adenomas in the large bowel
and untreated carriers inevitably develop colorectal
cancer at the age of 35–40 years (Bisgaard et al.,
1994). Patients with FAP also have increased risk of
developing extra-colonic manifestations, such as duode-
nal adenomas, fundic gland polyps, desmoid tumors,
osteomas and lipomas. Desmoid tumors have a pre-
valence of 10–20% in FAP patients, and are a major
cause of morbidity and mortality. A milder form of FAP
also exists referred to as attenuated polyposis (AFAP).
The APC gene (5q21–q22) encodes several tissue-
speciﬁc transcripts in which the major transcript has
an open reading frame of 8543bp (Horii et al., 1993),
two promoter regions have been identiﬁed, 1A and 1B
(Lambertz and Ballhausen 1993; De Rosa et al., 2007;
Hosoya et al., 2009). Promoter 1B has not been
extensively studied, and has been proposed to have a
minor role in the regulation of the APC gene compared
with promoter 1A (Charames et al., 2008, Segditsas
et al., 2008, Tsuchiya et al., 2000). More than 1400
disease-causing mutations causing premature truncation
or absence of the APC protein are included in the
Human Gene Mutation Database (Stenson et al., 2009),
and the mutation detection frequency generally reported
in families with a classical FAP is around 80–90%.
A number of screening methods to detect mutations in
exons of APC exists, but as sequence-based methods
gradually are becoming more available and easy to use,
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www.nature.com/oncthis is the screening method that today dominate in
routine diagnostics. Together with multiplex ligation-
dependent probe ampliﬁcation (MLPA; Schouten et al.,
2002), widely used to detect copy-number variations
(CNVs) in deﬁned regions, the majority of disease-
causing mutations can be identiﬁed. However, detection
of point mutations and CNVs located in introns and in
the regulatory regions of the gene still constitute a
challenge. Imbalance in allele-speciﬁc expression (ASE)
of the two APC alleles as a cause of FAP has been
recognized in several families (Castellsague et al.,
2010a). In majority of the cases, no deleterious mutation
explaining the lowered expression levels has been found.
Higher proportions of patients without extra-colonic
manifestations have been observed in these families and
in APC-mutation-negative FAP families in general
(Moisio et al., 2002; Renkonen et al., 2005).
In this study, we have screened 54 FAP/AFAP
families for mutations in APC and in the largest and
ﬁrst enrolled family in the Swedish Polyposis Registry,
Family 1, we identiﬁed two adjacent large novel
deletions in the regulatory region of the gene. One of
the deletions included more than half of the promoter
1B. We have previously identiﬁed imbalance in ASE in
this family (Kanter-Smoler et al., 2008). The family
includes 150 individuals (seven generations), of whom 59
are affected.
Results
Mutation screening
In this study, 54 families with FAP or AFAP were
screened for mutations in APC. A deleterious mutation
was found in 97% of families with FAP and 26% of
families with AFAP, two of these families carried bi-allelic
MUTYH mutations (Table 1). We have previously
reported imbalance in ASE in Family 1 from the Swedish
Polyposis Registry (Kanter-Smoler et al., 2008), but the
mutation remained undetected, and that is why we
undertook this study in an attempt to reveal the mutation.
Analysis of CNVs in the APC region of Family 1 and
characterization of the deletions
Affymetrix Genome-Wide Human SNP Array 6.0
(Affymetrix, Santa Clara, CA, USA) was used to analyze
for CNVs (using copy-number (CN) probes and single-
nucleotide polymorphism (SNP) probes) in the chromo-
somal region of APC. Using this approach, a large
deletion of B61kb was found in the regulatory region of
the APC gene (Figure 1a). Primer walking and sequen-
cing of PCR products revealed two adjacent deletions
(Del 1 and Del 2), encompassing 18.7kb and 42.1kb,
respectively. The two deletions were separated by a
retained fragment of 1540bp (Figure 1b). The deletions
are located 46kb upstream of the coding region of APC
and the precise location of Del 1 was chr5:112,008,797_
112,027,564; and Del 2; chr5:112,029,076_112,071,227
according to the University of California, Santa Cruz
reference sequence March 2006 (National Center for
Biotechnology Information/hg18). Six affected and two
non-affected individuals were analyzed on the array
platform and all affected, but not the unaffected,
individuals carried the deletions. The deletions con-
tained 320bp of promoter 1B and further upstream
highly conserved regions and regulatory elements
including six transcription factor-binding sites (interfer-
on-regulatory factor-1, Nkx25, TATA, POU6F1 and
two OCT1-binding sites). The most highly conserved
region was the binding site for the most upstream
located OCT1 site.
Five additional affected and two unaffected family
members from Family 1 and 50 control individuals were
analyzed by PCR ampliﬁcation to conﬁrm the segrega-
tion of the deletion with the disease. The deletions were
detected in all of the affected individuals, but not in the
unaffected or in the normal controls. Ampliﬁcation of
the deleted region by two different primer pairs in one
affected individual is shown in Figure 1c. The same
region in unaffected family members is not possible to
amplify because of its size.
Determination of expression levels from promoter 1A and
1B in blood from Family 1 using quantitative–PCR
(Q–PCR) and expression arrays
The consequence the deletions had on the transcription
of the APC gene was investigated using Q–PCR
(TaqMan; Applied Biosystems, Foster City, CA, USA)
and exon-speciﬁc expression arrays (Affymetrix Gene
Chip Human Exon 1.0 ST Array). A reduced expression
of APC was detected in affected individuals com-
pared with control individuals with both methods. A
schematic illustration over the locations of the different
TaqMan probes is presented in Figure 2. APC1 binds to
transcripts generated from the promoter 1B; APC2 and
APC3 bind to different transcripts from promoter 1A
and APC4; and APC5 binds to all transcripts generated
from both promoters 1A and 1B. Approximately a
threefold reduction in relative expression values was
observed in affected individuals compared with a
healthy family member and controls for APC1 (1B) and
APC4 (1Aþ1B) and at least a twofold reduction with
APC5 (1Aþ1B). The probes APC2 (1A) and APC3
(1A) demonstrated unexpectedly at least a threefold
higher expression in the affected patients compared with
normal controls (Figure 3). For a more comprehensive
illustration of the Q–PCR data, we have used normal-
ization where the sample with the lowest expression for
each assay is set to zero. Statistical signiﬁcance was
determined with the t-test, and was calculated for all of
the assays. All assays had P-values o0.001.
Analyses using the expression array resulted in a
twofold reduction in the overall expression of the APC
gene in affected family members compared with ﬁve
controls (data not shown). Twofold reduction in
expression represents a theoretically 50% downregula-
tion in gene expression. The expression array analysis
of affected individuals in Family 1 also revealed a
splice variant lacking exon 2 (besides the lower APC
expression, Figure 4). This splice variant was not
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Oncogenedetected in unaffected individuals from the family, or in
healthy controls. To elucidate the signiﬁcance of this
splice variant a panel of 20 normal tissues was analyzed
for its presence. The splice variant seemed to be more
abundant in heart and brain, though it was present in
normal colon mucosa as well (data not shown).
Determination of expression levels from promoter 1A and
1B in normal tissues from healthy controls using Q–PCR
A panel consisting of 20 different normal tissues was
examined for the expression of transcripts from the two
promoters (Figure 5). Transcripts from promoter 1B
(APC1) were expressed in all tissues. The relatively
highest expression for all of the transcripts was detected
in brain. In blood and colorectal mucosa, the expression
from promoter 1B (APC1) is approximately equal,
whereas expression from promoter 1A (APC2 and
APC3) in blood is much lower compared with colorectal
mucosa. (It is easy to get false impression from Figure 5
that the expression from promoter 1A is higher
compared with 1B, as staples are higher, however, this
only reﬂects the fact that the variation in relative
expression levels between the tissues is greater for
promoter 1A compared with 1B). An estimation of
absolute expression levels from the Cq-values (Supple-
Table 1 Mutations in FAP and AFAP patients
Patient FAP/AFAP Location Mutation Reference
C152, P4
(Family 1)
FAP Promoter 1B
(320 bp deletion)
chr5:g.[112,008,797_112,027,564del;112,029,076_112,071,227del] This study
C1929 FAP Gene chr5:g.(112,112,483_112,112,538)_(112,226,776_112,232,783)del This study
C1040 FAP Promoter 1A and gene chr5:g.(112,091,076_112,092,095)_(112,208,168_112,209,500)del This study
C1466 FAP Promoter 1A, 1B and gene chr5:g.(106,255,243_106,255,351)_(112,284,218_112,288,290)del This study
C2348 FAP Promoter 1A, 1B and gene chr5:g.(110,965,499_110,966,476)_(112,997,172_112,997,631)del This study
C2474 AFAP Exon 2–3 (duplication) NM_000038.3:c.136_422dup, p.Ser142_Val2843delins23X Mutoh et al. (2006)
C1563 AFAP Exon 3 NM_000038.3:c.422-3_456del, p.Arg141GlyfsX14 This study
C2420 FAP Exon 5 NM_000038.3:c.637C>T, p.Arg213X Miyoshi et al. (1992)
C2027 FAP Exon 6 NM_000038.3:c.694C>T, p.Arg232X Miyoshi et al. (1992)
C2462 FAP Exon 7 NM_000038.3:c.790C>T, p.Gln264X Cowie et al. (2004)
C1946 AFAP Exon 9 NM_000038.3:c.1263_1272delins19, p.Trp421X This study
C1079 FAP Exon 11, intron 10 NM_000038.3:c.1409-1G>A, p.? Kaufmann et al. (2009)
C1867 FAP Exon 11, intron 10 NM_000038.3:c.1409-1G>A, p.? Kaufmann et al. (2009)
C2240 FAP Exon 11, intron 10 NM_000038.3:c.1409-1G>A, p.? Kaufmann et al. (2009)
C1858 FAP Exon 11–13 (deletion) NM_000038.3:c.1419_1902del, p.Ala474GlufsX11 Andreutti-Zaugg et al. (1999)
C1992 FAP Exon 11, intron 11 NM_000038.3:c.1548þ1G>A, p.? Kohoutova et al. (2002)
C1097 FAP Exon 13 NM_000038.3:c.1660C>T, p.Arg554X Fodde et al. (1992)
C2321 FAP Exon 15 NM_000038.3:c.2006T>G, p.Leu669X This study
C1787 FAP Exon 15 NM_000038.3:c.2098dup p.Asp700GlyfsX6 This study
C1759 FAP Exon 15 NM_000038.3:c.2413C>T, p.Arg805X Dobbie et al. (1996)
C2383 FAP Exon 15 NM_000038.3:c.2547_2550del, p.Asp849GlufsX11 Ripa et al. (2002)
C2159 FAP Exon 15 NM_000038.3:c.3180_3184del, p.Gln1062X This study
C2296 FAP Exon 15 NM_000038.3:c.3183_3187del, p.Gln1062X Miyoshi et al. (1992)
C2609 FAP Exon 15 NM_000038.3:c.3183_3187del, p.Gln1062X Miyoshi et al. (1992)
C2195 FAP Exon 15 NM_000038.3:c.3537_3538del, p.Tyr1179X This study
C1327 FAP Exon 15 NM_000038.3:c.3927_3931del, p.Glu1309AspfsX4 Miyoshi et al. (1992)
C2643 FAP Exon 15 NM_000038.3:c.3927_3931del, p.Glu1309AspfsX4 Miyoshi et al. (1992)
C1579 FAP Exon 15 NM_000038.3:c.4132del, p.Gln1378ArgfsX37 This study
C2574 FAP Exon 15 NM_000038.3:c.4391_4394del, p.Glu1464ValfsX8 Gismondi et al. (1997)
C1893 FAP Exon 15 NM_000038.3:c.4570del, p.Ile1524X This study
C2300 FAP Exon 15 NM_000038.3:c.4612_4613del, p.Glu1538IlefsX5 Gayther et al. (1994)
C1784 FAP Exon 15 NM_000038.3:c.4638_4642del, p.Asn1546LysfsX11 Miyoshi et al. (1992)
C1897 FAP Exon 15 NM_000038.3:c.4655_4656del, p.Glu1552GlyfsX6 Nilbert et al. (2000)
C1807 AFAP Exon 15 NM_000038.3:c.7709dup, p.Ser2571IlefsX12 This study
C1189 FAP No mutation detected in APC or MUTYH
C1369 AFAP No mutation detected in APC or MUTYH
C1387 AFAP No mutation detected in APC or MUTYH
C1421 AFAP No mutation detected in APC or MUTYH
C1427 AFAP No mutation detected in APC
C1477 AFAP No mutation detected in APC
C1488 AFAP No mutation detected in APC
C1491 AFAP No mutation detected in APC
C1492 AFAP No mutation detected in APC
C1507 AFAP No mutation detected in APC or MUTYH
C1651 AFAP No mutation detected in APC nor MUTYH Y179C or G396D
C1813 AFAP No mutation detected in APC
C2081 AFAP No mutation detected in APC or MUTYH
C2110 AFAP No mutation detected in APC nor MUTYH Y179C or G396D
C2201 AFAP No mutation detected in APC nor MUTYH Y179C or G396D
C2292 AFAP No mutation detected in APC or MUTYH
C2341 AFAP No mutation detected in APC nor MUTYH Y179C or G396D
C2363 AFAP No mutation detected in APC nor MUTYH Y179C or G396D
C476 AFAP MUTYH NM_001128425.1:[c.1214C>T]þ[c.1214C>T], [p.P405L]þ[p.P405L]
C1590 AFAP MUTYH NM_001128425.1:[c.538G>A]þ[c.538G>A], [p.G189E]þ[p.G189E]
Abbreviations: AFAP, attenuated familial adenomatous polyposis; APC, adenomatous polyposis coli; FAP, familial adenomatous polyposis;
NCBI, National Center for Biotechnology Information.
Genomic localizations according to University of Califonia, Santa Cruz, reference sequence March 2006 (National Centre for Biotechnology
Information/hg18).
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Figure 1 (a) The deletion in two affected members, P1 and P3, of Family 1 analyzed with Affymetrix Genome-Wide Human SNP
Array 6.0 (analysis output from Genotyping Console; Affymetrix). The deletion (indicated by a red circle), which actually contains two
deletions (not possible to discover in this array data), is approximately 61kb. The transcript variant NM_000038.3 starts from
promoter 1A and transcript variant NM_001127511.1 starts from promoter 1B. (b) Schematic illustration of the deleterious allele and
the normal allele in Family 1. In the deleterious allele, the second deletion (Del 2) includes 320bp of promoter 1B (586bp as a whole)
of the APC gene. The deleterious allele carries a T in the heterozygous SNP position c.5465, whereas the normal allele carries an A. (c)
Agarose gel after separation of fragments generated from ampliﬁcation of the region upstream of APC where the deletions are located.
Sample P1,1 is a mutation carrier in which a fragment of B4kb is obtained after PCR ampliﬁcation with primers 256 and 343
(Supplementary Table 3), P1,2, an B3kb fragment obtained by ampliﬁcation of primers 256 and 1428 in the same patient. Samples
P2,1 and P2,2; ampliﬁcation using primers 256 together with 343 and 256 together with 1428 in an unaffected family
member which should have given fragments of B65kb and B64kb, respectively, but fragments this long is not possible to amplify
with conventional PCR. PCR-ampliﬁcation of a fragment of known size (450bp) is carried out simultaneously with the deletion-
speciﬁc primers to verify the presence of DNA in the reaction tube.
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Figure 2 Schematic illustration of the location of the ﬁve different TaqMan probes used in the Q–PCR of the APC gene. APC1 binds
speciﬁcally to the reference sequence NM_001127511.1 (probe located in exon 1B, for precise location see http://www.appliedbio-
systems.com Hs01568282_m1 Taqman gene expression assay), APC2 binds speciﬁcally to the reference sequence NM_000038.4 (probe
located in sequence speciﬁc for transcripts generated from promoter 1A, Chr. 5:g.112073556_112090642 (March 2006 (National Center
for Biotechnology Information/hg18) map)), APC3 binds speciﬁcally to the reference sequence NM_001127510.1 (probe located in
exon speciﬁc for transcripts from 1A, Chr. 5:g.112073579_112074157 (March 2006 (National Center for Biotechnology Information/
hg18) map)), APC4 and APC5 binds to all of the transcripts generated from both of the promoters. (For precise location see http://
www.appliedbiosystems.com Taqman gene expression assay, Hs01568270_m1 for APC4 and Hs00181051_m1 for APC5.)
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Figure 3 Expression in blood from the two promoters in patients and normal controls as measured by Q–PCR (TaqMan) by the ﬁve
assays, APC1–APC5. Samples S1–S10 are normal controls and P1–P4 are individuals from Family 1 were P1, P3 and P4 are affected
individuals (mutation carriers) and P2 is an unaffected individual. The data is normalized to zero for the sample with the lowest
expression for each assay. The error bars indicate the standard deviation for the RT replicates. (a) APC1 corresponds to transcript
NM_001127511.1 from promoter 1B. (b) APC2 corresponds to transcript NM_000038.4 from promoter 1A. (c) APC3 corresponds to
transcript NM_001127510.1 from promoter 1A. (d) APC4 corresponds to all transcripts generated from both of the promoters, 1A and
1B. (e) APC5 corresponds to all transcripts generated from both of the promoters, 1A and 1B.
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Oncogenementary Table 1) gives that in blood from normal
controls the transcript NM_001127511.1 (APC1) from
promoter 1B is expressed at B100-fold higher levels
than the transcript NM_000038.4 (APC2) from promo-
ter 1A, and B1000-fold higher than transcript
NM_001127510.1 (APC3) from promoter 1A.
Determination of expression levels from promoter 1A
and 1B in normal colon mucosa and adenoma tissue
from Family 1 using Q–PCR
The relative expression of the promoters in adenoma
and normal colon mucosa from three mutation carriers
and normal colon mucosa from control individuals were
determined (Figure 6). The normal colon mucosa from
the mutation carriers presented with lower relative
expression levels for all transcripts compared with
normal mucosa from control individuals. Comparison
of all the three adenoma tissues with normal colon
mucosa from patients demonstrated lower levels for all
transcripts in two of the samples. One of the samples
(P3) did not show a clear difference between normal and
adenoma tissues. The reason for this could be contam-
ination of normal tissue in the adenoma sample. For
APC1, APC4 and APC5, a statistical signiﬁcance of P-
values o0.006 was calculated. For APC2 and APC3 (P-
values o0.01), very low expression levels were observed,
and this is a reason why high standard deviations are
obtained. From the Cq-values (Supplementary Table 1),
an estimation of the total amount of transcription from
promoter 1B (APC1) and 1A (APC2 and APC3) in
normal colorectal mucosa was estimated. Transcript
NM_001127511.1 (APC1, 1B) was expressed around 250
times higher than transcript NM_001127510.1 (APC3,
1A) and 25 times higher than transcript NM_000038.4
(APC2, 1A) in this tissue.
Determination of methylation status and ASE and
characterization of the mechanism for APC inactivation
underlying tumor initiation in Family 1
To characterize the mechanisms of inactivation of
APC underlying tumor initiation, sequencing of the
coding region of the APC gene including the promoter
1A, analyses of methylation status and determination of
ASE in adenoma and normal colorectal mucosa were
carried out. Adenomas were available from four patients
and normal colorectal mucosa from three patients.
Sequencing over a heterozygous coding SNP (c.5465
A/T, Figure 1b) on complementary DNA (cDNA) was
performed to estimate total ASE of the APC gene. The
analysis revealed the deleterious T allele to be absent in
all four adenomas but still present at levels of 8–9%, in
two out of three of the normal colon mucosa tissues as
well as in blood lymphocytes from one individual (three
adenomas are shown in Figure 7). Using methylation-
speciﬁc MLPA, the methylation degree of the promoter
1A was determined to be 2, 10, 10 and 21% in the four
adenomas, respectively. In normal colon mucosa, only
very low degrees of methylation (3%) were observed in
two out of the three individuals. The methylation degree
of promoters required to have an effect on transcription
has been considered to correspond to B15% of methyl-
ated DNA (Judson et al., 2006). Accordingly, only one
patient from Family 1 demonstrated functional signiﬁ-
cant methylation of promoter 1A (P3, 21%) in adenoma
tissue. No mutation in the APC gene or in the promoter
1A in adenomas was detected.
Discussion
In this study, we report two adjacent large deletions
in the regulatory region of APC as causative for the
reduced expression and development of FAP in Family 1
of the Swedish Polyposis Registry. The deletions
include approximately half of the upstream region of
promoter 1B. This promoter has not been extensively
studied, and has been proposed to have a minor role
in the regulation of the APC gene compared with
promoter 1A (Charames et al., 2008; Segditsas et al.,
2008; Tsuchiya et al., 2000). In a recent study by
Charames et al. (2008), the ﬁrst deletion of promoter 1A
was found in a family with classical FAP (the deletion
did not involve the coding region of the gene). A
complete silencing of the transcription from the altered
allele was caused by the deletion. However, the precise
limits of the deletion could not be established, and it is
possible that this deletion also encompass promoter 1B.
Deletions of promoter 1B solely have so far not been
found in any FAP family.
To demonstrate the signiﬁcance of promoter 1B, we
have examined the activity of this promoter in relation
to promoter 1A in normal tissues from controls. We
have shown that signiﬁcant levels of transcripts are
generated from promoter 1B in blood and in colorectal
mucosa, as well as in a number of additional normal
tissues. We estimated absolute levels of expression from
promoter 1B to be 25- and 250-fold higher compared
with two different transcripts generated from 1A in
normal colorectal mucosa and 100- and 1000-fold higher
for each transcript in blood. The relatively highest levels
of transcription from promoter 1B were observed in
blood, brain and small intestine. In a recent study by
Hosoya et al. (2009), transcription from promoter 1B in
human normal gastric mucosa was estimated to be
15-fold higher as compared with levels from the
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Oncogenepromoter 1A. It is thus established that promoter 1B has
an important role in the regulation of APC in a variety
of normal tissues.
Reduced ASE of the APC gene has been shown to be
associated with a predisposition to FAP. The degree of
expression reduction for one allele has been variable,
ranging from around 50% to complete silencing
(Venesio et al., 2003; Renkonen et al., 2005; Kanter-
Smoler et al., 2008; Castellsague et al., 2010b). There
also seems to be a phenotypic variation due to the
changes in gene expression, and a threshold for APC
product being required to suppress intestinal tumorigen-
esis (Solomon et al., 1987; Yan et al., 2002). To further
assess the consequence of the deleted promoter region,
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Figure 5 Expression from the two promoters in a panel of normal tissues as measured by Q–PCR (TaqMan) by the ﬁve assays,
APC1–APC5. The data is normalized to zero for the sample with the lowest expression for each assay. (a) APC1 corresponds
to transcript NM_001127511.1 from promoter 1B. (b) APC2 corresponds to transcript NM_000038.4 from promoter 1A. (c) APC3
corresponds to transcript NM_001127510.1 from promoter 1A. (d) APC4 corresponds to all transcripts generated from both of the
promoters, 1A and 1B. (e) APC5 corresponds to all transcripts generated from both of the promoters, 1A and 1B.
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Oncogenewe have made a thorough study of the effect the deletion
has on the transcription of APC in mutation carriers.
We have used two different approaches for this study.
Analyses of relative expression levels of speciﬁc tran-
scripts generated from each promoter separately and
also from the total expression from both of the
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Figure 6 Expression from the two promoters measured in normal colon mucosa (P1-N, P3-N and P4-N) and adenoma (polyps, P1-P,
P3-P and P4-P) from mutation carriers and normal colon mucosa from healthy controls (colon-N-1 and colon-N-2) as measured by
Q–PCR by the ﬁve assays, APC1–APC5. The data is normalized to zero for the sample with the lowest expression for each assay. The
error bars indicate the standard deviation for the RT replicates. (a) APC1 corresponds to transcript NM_001127511.1 from promoter
1B. (b) APC2 corresponds to transcript NM_000038.4 from promoter 1A. (c) APC3 corresponds to transcript NM_001127510.1 from
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Normal colon mucosa Adenoma Blood lymphocytes
Figure 7 cDNA sequencing over the cSNP c.5465 A/T in affected family members of Family 1. Allele-speciﬁc expression was
determined by visual estimation. The A allele (normal) is green and the T allele (deleterious) is red. (a) Patient P4, normal colorectal
mucosa; 100% A, B8% T, adenoma; 100% A, B0% T, blood lymphocytes; 100% A, B9% T. (b) P1, normal colorectal mucosa;
100% A, B0% T, adenoma; 100% A, B0% T. (c) P3, normal colorectal mucosa; 100% A, B9% T, adenoma; 100% A, B0% T.
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Oncogenepromoters in combination was carried out by Q–PCR
(TaqMan). We also used sequencing over a hetero-
zygous cDNA polymorphism (c.5465 A/T) to estimate
the overall ASE in mutations carriers. Expression levels
were measured in blood, normal colorectal mucosa and
adenoma from mutation carriers. In the normal colon
mucosa from mutation carriers, a level of B10%
expression of the deleterious allele was determined using
cDNA sequencing. No detectable expression of the
deleterious allele could be observed in the adenomas
indicating allele loss. The reason for the loss of
deleterious allele in one of the normal colorectal mucosa
samples is probably because of the fact that this sample
was taken close to the adenoma. The Q–PCR results
indicate markedly lowered levels of expression from
promoter 1B in mutation carriers. Unexpectedly in
blood, elevated levels of expression from promoter 1A
are observed. The reason for this could be tissue-speciﬁc
compensation of 1A transcription due to the damaged
promoter 1B (Fiering et al., 1999). However, this
compensation is not seen in samples from normal colon
mucosa and adenoma from mutation carriers. As we
have described above, estimation of absolute expression
levels for promoter 1B in blood from normal controls
indicate that 1B is expressed in considerably higher
amounts compared with 1A, which is also obvious when
relative expression levels from both promoters (APC4
and APC5, Figure 3) are examined, as those levels are
more equal to expression from 1B than 1A. In view of
these observations, it is straightforward to state that the
inactivation of promoter 1B, caused by the deletion we
identiﬁed in this study, is a cause of FAP in carriers. In
Family 1, we have ruled out other possible mechanisms
of inactivation of APC, such as mutations in the coding
and promoter regions and also partly in the intronic
regions. Involvement of mutations affecting mRNA and
inactivation caused by promoter methylation has also
been excluded as well as chromosomal aberrations.
Apparently no loss of heterozygosity of the normal
allele (A allele) is present in the adenomas. If there is a
concordance with the study by Renkonen et al. (2005), a
complete loss of heterozygosity of the normal allele, not
involved in the germline alteration, should be expected
in tumors. We were not able to obtain tumors from
Family 1 for this study, as colorectal cancer is rare in
affected members living today. Aberrant Wnt signaling
with nuclear accumulation of b-catenin, following
homozygous inactivation of APC, has been the govern-
ing model for tumor initiation in FAP, and germline
mutations are believed to dictate the second hit in APC
in FAP, and thus, indirectly affect the severity of the
disease. Two or three out of seven 20-amino-acid repeats
in the central domain of APC, which give an optimal
level of b-catenin required for tumor formation, seem to
be required for tumorigenesis. Consequently, in FAP
patients with whole gene deletions, all second somatic
hits should be in the mutation cluster region in exon 15
leaving two or three of the repeats intact. However,
sequence analyses of the adenomas in this family did
not reveal any inactivating mutation at all in this region
of the gene or in the entire gene including promoter 1A
(mutations could though be present in tumors). Emerging
evidence points to an alternative model for adenoma
initiation in which APC mutations induces adenoma
formation through dysregulation of C-terminal binding
protein-1 (Hamada and Bienz, 2004, Sierra et al.,2 0 0 6 )
rather than activation of b-catenin (Phelps et al.,
2009a,b). It has been demonstrated that nuclear localiza-
tion of b-catenin is not present in the early adenomas
(Amos-Landgraf et al., 2007, Blaker et al.,2 0 0 3 ) ,a n d
that b-catenin requires mutations of additional genes for
nuclear accumulation and activation of the cell-prolifer-
ating genes. The fact that we, in adenomas from mutation
carriers, cannot detect homozygous inactivation of APC
support this model, as the initiation of adenoma
formation in the carriers occurs independently of the
favored number of 20-amino-acid repeats, and, therefore,
is independent of b-catenin levels. Instead additional
mutations in other genes might be necessary.
Hypermethylation of CpG islands in the promoters
1A, but not 1B, of APC has been reported as a cause of
gene silencing in sporadic tumors and tumors from
FAP patients, but no methylation has been detected in
normal colon mucosa (Hiltunen et al., 1997; Esteller
et al., 2000; Segditsas et al., 2008). We examined the
adenomas for methylation status, and as all adenomas
had low-grade dysplasia, we would expect very low
methylation levels, which was the case in all but one
sample. However, this might be a random event, and as
this was just one sample from one individual no further
conclusion can be made.
The absence of desmoid tumors in the large Family 1
is striking, and except for osteomas and lipomas other
extra-intestinal manifestations seem to be rare. Less
frequent occurrence of extra-colonic manifestations in
FAP patients with reduced expression have also been
reported in other studies (Moisio et al., 2002; Renkonen
et al., 2005). The fact that mutation carriers in Family 1
retain B10% expression of the deleterious allele
and demonstrate an increased expression from promoter
1A in blood but not in colorectal mucosa could
be of importance. It could well be that elevated
expression levels from promoter 1A also are present in
other tissues in Family 1, which could be an explanation
for less frequent manifestations in other organs in the
family.
We used the recently introduced Affymetrix Genome-
Wide Human SNP 6.0 CNV arrays, with an average
spacing of 0.7kb between probes in this study. This
resolution is required to identify CNVs of the sizes we
describe. Even if the resolution of this array is adequate
to detect CNVs as small as this, it is difﬁcult to discover
very small deviations of single or a few probes, which is
exempliﬁed by the fact that we could not detect the
retained region (1.5kb) between the two deletions in
Family 1 in the array analyses. We suggest that in
families displaying a classical FAP phenotype with no
deleterious mutation identiﬁed, screening for CNVs in
the regulatory regions of APC should follow the initial
screening of the coding region as mutations located
upstream of promoter 1A could be a possible causative
alteration.
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Patients and material
We analyzed 54 FAP and AFAP families in this study. The
majority of families are registered in the Swedish Polyposis
Registry. Family 1 was the ﬁrst family enrolled in the Registry
in the late 1950s. It is by far the largest pedigree in the registry,
including seven generations (150 individuals), with 59 veriﬁed
FAP cases, of whom 24 were probands with a mean age at
diagnosis of 38.3 (range, 26–71) years. The clinical manifesta-
tions of the individuals are described in Supplementary
Table 2. Of the 35 call-up patients, with a mean age of 19
(range, 8–36) years at diagnosis, none had colorectal cancer at
surgery. In patients examined with gastroscopy, duodenal
adenomas were diagnosed in 93% of the cases for which we
had data. One patient had a duodenal cancer and four have
been prophylactically operated with duodenectomy. Benign
extra-intestinal manifestations were exclusively osteomas
and lipomas, only one malignant extra-intestinal manifestation
has so far been discovered, and none of the patients have
developed desmoid tumors. Adenoma and normal colon
mucosa (localized close to the adenoma) were examined from
four patients in this family. All of the adenomas were classiﬁed
as low-grade dysplasia. Blood donors were used as healthy
controls. All patients gave their consent, and the study has
been approved by the local ethics committee at the Karolinska
Institute in Stockholm and at the University of Gothenburg.
All index patients included in this study have been screened
for germline mutations in the coding region of APC
(NM_000038.3) as described by Kanter-Smoler et al. (2008).
The FAP/AFAP-mutation-negative patients were in some
cases screened for the two most frequent mutations in
MUTYH (NM_001128425.1) or the whole gene, see Table 1.
The Human Gene Mutation Database database and The
Colon Cancer Gene Variant Database (http://www.LOVD.
nl/APC) were used to control if the identiﬁed mutations in
APC had been reported previously. Family 1 has been
extensively screened for mutations including sequencing of
promoter regions and also B50% of the intron sequences,
as well as analyses of promoter methylation (in blood
lymphocytes). To detect second-hit mutations in adenomas,
the APC-coding region and promoter 1A was also sequenced.
To rule out any chromosomal aberrations linked to
the deleterious genotype, two affected members were also
karyotyped.
DNA, RNA, cDNA preparation and karyotyping
Genomic DNA was extracted using the BioRobot EZ1
(Qiagen, Hilden, Germany) with the EZ1 DNA Blood 350ml
kit (Qiagen). DNA was extracted from tissues from adenomas
and normal colon mucosa using QiaAmp DNA microkit
(Qiagen). Blood samples were collected into PAXgene Blood
RNA tubes (Qiagen) and RNA was extracted using PAXgene
Blood RNA kit (Qiagen) and from tissue samples using the
RNeasy Mini kit (Qiagen). The RNA samples used from
normal tissues (except blood) were the Human Total RNA
Master Panel II (Clontech Laboratories, Mountain View, CA,
USA), which was used to evaluate the aberrant transcript
lacking exon 2 and the FirstChoice Human Total RNA Survey
Panel (Ambion, Applied Biosystems), which was used in the
Q–PCR analyses together with a separate sample from normal
colorectal mucosa from the same distributor. cDNA was
synthesized using Superscript system for reverse transcriptase–
PCR (Invitrogen GmBH, Karlsruhe, Germany). Spreads
from metaphase chromosomes were prepared from cultured
lymphocytes as described in Johannesson et al. (1991).
Ampliﬁcation, sequence analyses and MLPA
Ampliﬁcation, puriﬁcation and sequencing were carried out as
described previously (Kanter-Smoler et al., 2008). Primers
used for direct sequencing were identical to those used in the
ampliﬁcation reactions. The primer sequences for the exons
and promoter regions are given in Supplementary Table 3, and
the cDNA primers are described in De Rosa et al. (2007). CN
detection by MLPA was performed according to the protocol
provided by the supplier using the SALSA MLPA kit P043
APC (version B1, MRC-Holland, Amsterdam, the Nether-
lands). The MLPA data were analyzed using GeneMapper 4.0
genotyping software (Applied Biosystem) and SeqPilot version
3.3.2 (JSI medical systems, GmBH, Kippenheim, Germany).
Expression analyses using Affymetrix Gene Chip Human Exon
1.0 ST arrays
Quantiﬁcation of RNA was made using Nanodrop ND-1000
UV-spectrophotometer (NanoDrop Technologies, Wilming-
ton, Delaware, IL, USA), and RNA quality was assessed using
RNA 6000 Nanochips with Agilent 2100 Bioanalyzer (Agilent
Technologies, Palo Alto, CA, USA). RNA (1mg) from samples
with RNA integrity numbers between 7 and 10 were analyzed.
Three technical replicates were used for each sample.
Ribosomal RNA was removed using RiboMinus Human
Transcriptome Isolation (Invitrogen). Samples were prepared
according to standard conditions (Affymetrix). Washing and
staining of arrays were performed on the GeneChip Fluidics
station 450 (Affymetrix).
Data analysis
Analysis of raw data was performed with the expression
console software from Affymetrix. A principle component
analysis was conducted to identify outliers in the samples. The
control spikes and hybridization metrics were evaluated as
described by Affymetrix.
Analyses of the data was also carried out using the Partek
Genomics Suites 6.4 software (Partek Inc., St Louis, MO,
USA). The robust multichip average algorithm was used for
probe set intensity analysis. The data was ﬁltered to include
only the core probe set. Analysis of variance in the Partek
software was used for calculation of P-values to identify
expression fold changes and splicing events. A decrease in fold
change by a factor 2 corresponds to approximately a 50%
downregulation in gene expression.
CNV detection using Affymetrix Genome-Wide Human SNP
Array 6.0
The GeneChip 6.0 platform includes about 906600 SNP and
about 900000 CN probes, covering the whole genome with an
average spacing of B0.7kb. Samples were prepared according
to standard conditions (Affymetrix). Puriﬁcation of PCR
products was performed using Magnetic Beads (Agencourt
Bioscience Corporation, Beverly, MA, USA). Hybridization,
washing and staining of arrays was performed as described by
the supplier (Affymetrix).
Data analysis
Affymetrix Genotyping Console 3.0.1 was used for CN
analysis. The Genotyping Console Contrast Quality Control
metric was used to ﬁlter out low-quality samples using the
default threshold of 40.4. For the CN analysis the Median
Absolute Pairwise Difference value threshold was set to
p0.35. The Affymetrix HapMap 270 Reference Model was
used for the analysis. Statistical analysis was carried out with
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GC correction and the Hidden Markov model.
Isolation and veriﬁcation of the deleted region
Primer walking was used to map the two breakpoints in
Family 1, the primers can be obtained from the author upon
request. The PCR primers used for the veriﬁcation of the
deletions were forward primer: 50-CCAGGGAACTCAAT
CAAGGA-30 (chr5:111980705–111980724) and reverse
primer: 50-CTACCGCTTTGATCCCACAT-30 (chr5:112044642–
112044661). These primers ampliﬁed a fragment of B3kb in
deletion carriers and was absent in non-carriers. The PCR
fragment was sequenced with internal primers (can be obtained
from the author upon request) to reveal the break points.
Promoter methylation analysis by sequencing and MLPA
The presence of DNA methylation at CpG dinucleotides in
the APC promoter 1A (accession number U02509) and 1B
(accession number D13981) was determined using bisulphite
sequencing. The DNA samples were treated with the Epitec
bisulphite kit (Qiagen). The primers and conditions were
according to Romero-Gimenez et al. (2008). Methylation-
speciﬁc MLPA analysis was performed using the SALSA
MLPA kit ME001 Tumor suppressor-1 (MRC-Holland). This
kit contains one methylation-speciﬁc probe in promoter 1A of
the APC gene. The probe is located 72bp upstream of exon 2
(NM_000038.4). The MLPA results were analyzed using
GeneMapper 4.0 genotyping software (Applied Biosystems)
and SeqPilot version 3.3.2. Methylation dosage ratio was
calculated according to Joensuu et al. (2008).
Q–PCR performed using TaqMan gene expression assays
Five different TaqMan probes were obtained from Applied
Biosystems. The APC 1 probe (Hs01568282_m1) is speciﬁc for
transcript NM_001127511.1 expressed from promoter 1B,
APC2 is speciﬁc for NM_000038.4 expressed from promoter
1A, APC3 is speciﬁc for NM_001127510.1 also expressed from
promoter 1A, whereas APC4 (Hs01568270_m1) and APC5
(Hs00181051_m1) bind to all transcripts generated from both
promoters. The APC2 and APC3 probes were designed by us
using the Custom TaqMan Expression Assays (Applied
Biosystems). Q–PCR was performed in 384-well plates using
the Applied Biosystems 7900HT fast real-time PCR system
(Applied Biosystems) or the Roche LightCycle 480 (Hoffman-
La Roche, Basel, Switzerland). Ampliﬁcations were carried out
in triplicates or in duplicates for the blood controls (S1–S10),
patient samples (P1–P4) and the colorectal mucosa and in
singlets for all the other tissues. The standard curve method
was used for the Q–PCR analyses. The relative expression
levels for each sample was calculated from the mean Cq-values
and CN were expressed as a fold difference relative to the
control samples. All samples were normalized against
glyceraldehyde 3-phosphate dehydrogenase (GAPDH), beta-
glucuronidase (GUSB) and TATA-binding protein (TBP). The
t-test was used to calculate statistical signiﬁcance. It is possible
to estimate absolute expression levels in Q–PCR by using the
fact that Q–PCR by TaqMan is an exponential reaction in
which a 10-cycle difference corresponds to a 1000-fold
difference in the amount of transcripts in a correctly designed
assay functioning properly in terms of speciﬁcity and
efﬁciency. The Cq-values obtained were compared between
the assays, and an estimate of absolute levels was made from
this raw data of the Q–PCR reactions. The amounts calculated
can serve as a guideline regarding the amount of transcripts.
The Q–PCR analyses were carried out at the TATAA
Biocenter AB and the Genomics Core Facility at the
Sahlgrenska Academy, University of Gothenburg (Gothen-
burg, Sweden).
Bioinformatics
To identify evolutionary conserved regulatory elements in the
deleted regions of Family 1, an alignment to 43 species using
the University of California, Santa Cruz database and the
ENSEMBL (European Molecular Biology Laboratory-
European Bioinformatics Institute and the Sanger Institute)
database was performed. The March 2006 (National Center
for Biotechnology Information/hg18) map was used for the
alignments in the University of California, Santa Cruz
database. Conserved regions were further analyzed in detail
to ﬁnd regulatory elements including transcription factor
binding sites, enhancer elements, expressed sequence tags and
open reading frames with open reading frame ﬁnder (http://
www.ncbi.nlm.nih.gov/projects/gorf/), TRANSFAC (http://
www.gene-regulation.com/pub/databases.html) for prediction
of transcription binding sites (Matys et al., 2006) and Enhancer
element locator (Palin et al., 2006; http://sbz-17.cs.helsinki.ﬁ/
Btkt_bsap/EELweb/). The region was also compared with
RIKEN data for CAGE (cap analysis gene expression)
transcripts in the region (Kawaji et al., 2009).
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